The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic factors in sinonasal cancers: A multicenter pooled analysis.
 
Alberto Hernando-Calvo
Travel, Accommodations, Expenses - Kyowa Kirin International; Merck Serono
 
Milica Stefanovic
No Relationships to Disclose
 
Shao Hui Huang
No Relationships to Disclose
 
Jesús Brenes Castro
Honoraria - Merck
Travel, Accommodations, Expenses - MSD Oncology
 
Jie Su
No Relationships to Disclose
 
Brian O'Sullivan
Consulting or Advisory Role - Merck
 
Jolie Ringash
No Relationships to Disclose
 
Alicia Lozano
Honoraria - MSD Oncology
 
Beatriz Cirauqui
Consulting or Advisory Role - Bristol-Myers Squibb; Merck; Roche
Speakers' Bureau - Bristol-Myers Squibb; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Roche
 
Ezra Hahn
No Relationships to Disclose
 
Iris Teruel
Speakers' Bureau - BMS; Roche
Travel, Accommodations, Expenses - Lilly
 
John R de Almeida
No Relationships to Disclose
 
Jordi Marruecos
No Relationships to Disclose
 
Ian Witterick
Stock and Other Ownership Interests - Proteocyte Diagnostics Inc.
Honoraria - Genzyme; GlaxoSmithKline
 
Jordi Rubió-Casadevall
Consulting or Advisory Role - Sanofi
 
David Paul Goldstein
Stock and Other Ownership Interests - Pfizer (I)
 
Lillian L. Siu
Leadership - Treadwell Therapeutics (I)
Stock and Other Ownership Interests - Agios (I)
Consulting or Advisory Role - Amgen; Arvinas; AstraZeneca/MedImmune; Daiichi Sankyo/UCB Japan; GlaxoSmithKline; Hookipa Pharma; InterRNA; Janpix; Janssen; Merck; Navire; Oncorus; Relay Therapeutics; Roche; Sanofi; Seagen; Tessa Therapeutics; Voronoi Health Analytics
Research Funding - Amgen (Inst); Amgen (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AVID Radiopharmaceuticals (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intensity Therapeutics (Inst); Karyopharm Therapeutics (Inst); Merck (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Shattuck Labs (Inst); Symphogen (Inst)
 
John Waldron
No Relationships to Disclose
 
Anna Spreafico
Honoraria - Bristol-Myers Squibb; Medison & Immunocore
Consulting or Advisory Role - Bristol-Myers Squibb; Medison & Immunocore; Merck; Novartis; Oncorus
Research Funding - Alkermes; Amgen (Inst); Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; GlaxoSmithKline; Janssen Oncology; Merck; Northern Biologics; Novartis; Replimune; Roche; Surface Oncology; Symphogen; Treadwell Therapeutics (Inst)
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Idera; Janssen Oncology; Merck; Roche
 
Marc Oliva
Honoraria - Merck; MSD Oncology; Transgene
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Pfizer; Merck; MSD Oncology
Other Relationship - Bristol-Myers Squibb; Merck; MSD Oncology